204 related articles for article (PubMed ID: 10829315)
21. Adjuvant therapies in extended pancreatectomy for ductal adenocarcinoma of the pancreas.
Ishikawa O; Ohigashi H; Sasaki Y; Masao K; Kabuto T; Furukawa H; Imaoka S
Hepatogastroenterology; 1998; 45(21):644-50. PubMed ID: 9684110
[TBL] [Abstract][Full Text] [Related]
22. Current status and future perspectives in gastric cancer management.
Roukos DH
Cancer Treat Rev; 2000 Aug; 26(4):243-55. PubMed ID: 10913380
[TBL] [Abstract][Full Text] [Related]
23. Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions.
Adham M; Jaeck D; Le Borgne J; Oussoultzouglou E; Chenard-Neu MP; Mosnier JF; Scoazec JY; Mornex F; Partensky C
Pancreas; 2008 Nov; 37(4):352-7. PubMed ID: 18665012
[TBL] [Abstract][Full Text] [Related]
24. [Surgical resection of pancreatic adenocarcinoma: indications and contraindications, pronostic factors and survival, recent advances].
Delpero JR
Cancer Radiother; 2004 Nov; 8 Suppl 1():S73-9. PubMed ID: 15679251
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant postoperative radiation therapy +/- 5-FU in resected carcinoma of the pancreas.
Foo ML; Gunderson LL
Hepatogastroenterology; 1998; 45(21):613-23. PubMed ID: 9684106
[TBL] [Abstract][Full Text] [Related]
26. An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma.
Stojadinovic A; Brooks A; Hoos A; Jaques DP; Conlon KC; Brennan MF
J Am Coll Surg; 2003 Jun; 196(6):954-64. PubMed ID: 12788434
[TBL] [Abstract][Full Text] [Related]
27. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Roy P; Scoazec JY
Am J Clin Oncol; 2008 Dec; 31(6):545-52. PubMed ID: 19060585
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry.
Stessin AM; Meyer JE; Sherr DL
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1128-33. PubMed ID: 18538501
[TBL] [Abstract][Full Text] [Related]
29. [Pancreatic carcinoma. Optimizing therapy by adjuvant and neoadjuvant therapy?].
Maurer CA; Zgraggen K; Büchler MW
Zentralbl Chir; 1999; 124(5):401-7. PubMed ID: 10420525
[TBL] [Abstract][Full Text] [Related]
30. [Patients with non-advanced pancreatic cancer benefit from extended lymphadenectomy].
Popiela T; Kedra B; Sierzega M; Kubisz A
Zentralbl Chir; 2002 Nov; 127(11):960-4. PubMed ID: 12476369
[TBL] [Abstract][Full Text] [Related]
31. Long term survival after pancreatic resection for pancreatic adenocarcinoma.
Ahmad NA; Lewis JD; Ginsberg GG; Haller DG; Morris JB; Williams NN; Rosato EF; Kochman ML
Am J Gastroenterol; 2001 Sep; 96(9):2609-15. PubMed ID: 11569683
[TBL] [Abstract][Full Text] [Related]
32. [Changes and complication rate in surgery for thoracic esophageal carcinoma].
Meyer T; Merkel S; Göhl J; Stumpf P; Hohenberger W
Zentralbl Chir; 2003 Aug; 128(8):631-9. PubMed ID: 12931257
[TBL] [Abstract][Full Text] [Related]
33. Survival in lymph node negative adenocarcinoma of the esophagus after R0 resection with and without neoadjuvant therapy: evidence for downstaging of N status.
Leers JM; Ayazi S; Hagen JA; Terterov S; Klipfel N; Oezcelik A; Abate E; Lipham JC; DeMeester SR; Banki F; DeMeester TR
J Am Coll Surg; 2009 Apr; 208(4):553-6. PubMed ID: 19476789
[TBL] [Abstract][Full Text] [Related]
34. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer?
Mansour JC; Tang L; Shah M; Bentrem D; Klimstra DS; Gonen M; Kelsen DP; Brennan MF; Coit DG
Ann Surg Oncol; 2007 Dec; 14(12):3412-8. PubMed ID: 17909917
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemotherapy, radical resection with intraoperative radiation therapy (IORT): improved treatment for gastric adenocarcinoma.
Weese JL; Harbison SP; Stiller GD; Henry DH; Fisher SA
Surgery; 2000 Oct; 128(4):564-71. PubMed ID: 11015089
[TBL] [Abstract][Full Text] [Related]
36. The role of paraaortic lymph node involvement on early recurrence and survival after macroscopic curative resection with extended lymphadenectomy for pancreatic carcinoma.
Shimada K; Sakamoto Y; Sano T; Kosuge T
J Am Coll Surg; 2006 Sep; 203(3):345-52. PubMed ID: 16931307
[TBL] [Abstract][Full Text] [Related]
37. New techniques and agents in the adjuvant therapy of pancreatic cancer.
Raraty MG; Magee CJ; Ghaneh P; Neoptolemos JP
Acta Oncol; 2002; 41(7-8):582-95. PubMed ID: 14651201
[TBL] [Abstract][Full Text] [Related]
38. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival.
Massucco P; Capussotti L; Magnino A; Sperti E; Gatti M; Muratore A; Sgotto E; Gabriele P; Aglietta M
Ann Surg Oncol; 2006 Sep; 13(9):1201-8. PubMed ID: 16955382
[TBL] [Abstract][Full Text] [Related]
39. [Multimodal treatment of non small cell lung cancer].
Stoelben E; Digel W; Henke M; Passlick B
Zentralbl Chir; 2006 Apr; 131(2):110-4. PubMed ID: 16612776
[TBL] [Abstract][Full Text] [Related]
40. Comparative outcome between chemoradiotherapy and lateral pelvic lymph node dissection following total mesorectal excision in rectal cancer.
Kim JC; Takahashi K; Yu CS; Kim HC; Kim TW; Ryu MH; Kim JH; Mori T
Ann Surg; 2007 Nov; 246(5):754-62. PubMed ID: 17968166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
